This double-blind, randomised controlled trial (RCT) involving individuals with mild to moderate PD, investigated the HiBalance programme in terms of behavioural outcomes and related changes in task-evoked brain activity and the neurotrophic factor BDNF. The gene discussed is BDNF; the disease is Parkinson disease.